Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature
Authors Cinone N, Letizia S, Santoro L, Gravina M, Amoruso L, Molteni F, Ranieri M, Santamato A
Received 13 December 2017
Accepted for publication 7 April 2018
Published 25 June 2018 Volume 2018:11 Pages 1239—1245
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Minal Joshi
Peer reviewer comments 3
Editor who approved publication: Dr Michael Schatman
Nicoletta Cinone,1 Sara Letizia,1 Luigi Santoro,1 Michele Gravina,2 Loredana Amoruso,1 Franco Molteni,3 Maurizio Ranieri,1 Andrea Santamato1,4
1Physical Medicine and Rehabilitation Unit, Ospedali Riuniti, Università di Foggia, Foggia, 2Rehabilitation Center, “Padre Pio” Foundation, San Giovanni Rotondo, 3“Villa Beretta” Rehabilitation Unit, Lecco, 4Rehabilitation Center, “Turati” Foundation, Vieste, Italy
Introduction: Shoulder pain is one of the most common musculoskeletal diseases, and can be due to glenohumeral osteoarthritis, rotator cuff tear, impingement, tendinitis, adhesive capsulitis, and subacromial bursitis. Several therapies have been proposed, including steroids, nonsteroidal anti-inflammatory drugs, intra-articular injections, and physical therapies. Many published studies have reported on the employment of botulinum toxin type A (BoNT-A) to reduce pain in subjects with neurological and musculoskeletal diseases by inhibiting substance P release and other inflammatory factors.
Methods: In the present article, we briefly update current knowledge regarding intra-articular BoNT therapy, reviewing existing literature on intra-articular use of BoNT-A, including nonrandomized and randomized prospective and retrospective cohort studies and case series published from December 1989 to November 2017. We also describe a case series of six subjects treated with intra-articular injection of incobotulinumtoxin A for the treatment of pain deriving from osteoarthritis.
Conclusion: Intra-articular BoNT-A is effective and minimally invasive. Pain reduction with an increase in shoulder articular range of motion in our experience confirms the effectiveness of BoNT-A injection for the management of this syndrome.
Keywords: shoulder-pain syndrome, botulinum toxin type A intra-articular injections, glenohumeral osteoarthritis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]